Pediatric Anthracycline‐Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem‐Cell Modeling

Anthracycline‐induced cardiotoxicity (ACT) is a severe adverse drug reaction for a subset of children treated with anthracyclines as part of chemotherapy protocols. The identification of genetic markers associated with increased ACT susceptibility has clinical significance toward improving patient c...

Descripción completa

Detalles Bibliográficos
Autores principales: Tripaydonis, Anne, Conyers, Rachel, Elliott, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590110/
https://www.ncbi.nlm.nih.gov/pubmed/30460992
http://dx.doi.org/10.1002/cpt.1311
_version_ 1783429486302199808
author Tripaydonis, Anne
Conyers, Rachel
Elliott, David A.
author_facet Tripaydonis, Anne
Conyers, Rachel
Elliott, David A.
author_sort Tripaydonis, Anne
collection PubMed
description Anthracycline‐induced cardiotoxicity (ACT) is a severe adverse drug reaction for a subset of children treated with anthracyclines as part of chemotherapy protocols. The identification of genetic markers associated with increased ACT susceptibility has clinical significance toward improving patient care and our understanding of the molecular mechanisms involved in ACT. Human‐induced pluripotent stem cell–derived cardiomyocytes represent a novel approach to determine the pharmacogenomics of ACT and guide the development of genetic screening tests.
format Online
Article
Text
id pubmed-6590110
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65901102019-07-08 Pediatric Anthracycline‐Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem‐Cell Modeling Tripaydonis, Anne Conyers, Rachel Elliott, David A. Clin Pharmacol Ther Reviews Anthracycline‐induced cardiotoxicity (ACT) is a severe adverse drug reaction for a subset of children treated with anthracyclines as part of chemotherapy protocols. The identification of genetic markers associated with increased ACT susceptibility has clinical significance toward improving patient care and our understanding of the molecular mechanisms involved in ACT. Human‐induced pluripotent stem cell–derived cardiomyocytes represent a novel approach to determine the pharmacogenomics of ACT and guide the development of genetic screening tests. John Wiley and Sons Inc. 2019-01-11 2019-03 /pmc/articles/PMC6590110/ /pubmed/30460992 http://dx.doi.org/10.1002/cpt.1311 Text en © 2018 Murdoch Childrens Research Institute. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Reviews
Tripaydonis, Anne
Conyers, Rachel
Elliott, David A.
Pediatric Anthracycline‐Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem‐Cell Modeling
title Pediatric Anthracycline‐Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem‐Cell Modeling
title_full Pediatric Anthracycline‐Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem‐Cell Modeling
title_fullStr Pediatric Anthracycline‐Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem‐Cell Modeling
title_full_unstemmed Pediatric Anthracycline‐Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem‐Cell Modeling
title_short Pediatric Anthracycline‐Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem‐Cell Modeling
title_sort pediatric anthracycline‐induced cardiotoxicity: mechanisms, pharmacogenomics, and pluripotent stem‐cell modeling
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590110/
https://www.ncbi.nlm.nih.gov/pubmed/30460992
http://dx.doi.org/10.1002/cpt.1311
work_keys_str_mv AT tripaydonisanne pediatricanthracyclineinducedcardiotoxicitymechanismspharmacogenomicsandpluripotentstemcellmodeling
AT conyersrachel pediatricanthracyclineinducedcardiotoxicitymechanismspharmacogenomicsandpluripotentstemcellmodeling
AT elliottdavida pediatricanthracyclineinducedcardiotoxicitymechanismspharmacogenomicsandpluripotentstemcellmodeling

Ejemplares similares